Filovirus epidemic in 1956 in Bili, DRC

Colebunders, Robert; Ende, Jef Van den

doi:10.1016/s1473-3099(15)70092-7

The Lancet Infectious Diseases

2015

DOI: 10.1016/s1473-3099(15)70092-7

|View full text |Cite

Filovirus epidemic in 1956 in Bili, DRC

Robert Colebunders¹,

Jef Van den Ende²

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

2017

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, we cannot rule out that more EBV outbreaks have occurred but were not recognized and thus not reported, since they are mainly located in isolated and remote forest areas, with poor health infrastructure and poor knowledge on the disease. A recent report on a possible filovirus outbreak in 1956 in DRC is in line with this hypothesis (9), and several studies reported the presence of antibodies (sometimes with high levels) in human populations in Central Africa (10).…”

mentioning

confidence: 59%

Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus

et al. 2017

View full text Add to dashboard Cite

The recent Zaire Ebola virus (EBOV) outbreak in West Africa illustrates clearly the need for additional studies with humans and animals to elucidate the ecology of Ebola viruses (EBVs). In this study, we developed a serological assay based on the Luminex technology. Nine recombinant proteins representing different viral regions (nucleoprotein [NP], 40-kDa viral protein [VP40], and glycoprotein [GP]) from four of the five EBV lineages were used. Samples from 94 survivors of the EBOV outbreak in Guinea and negative samples from 108 patients in France were used to calculate test performance for EBOV detection and cross-reaction with other Ebola virus lineages. For EBOV antibody detection, sensitivities of 95.7%, 96.8%, and 92.5% and specificities of 94.4%, 95.4%, and 96.3% for NP, GP, and VP40, respectively, were observed. All EBOV-negative samples that presented a reaction, except for one, interacted with a single antigen, whereas almost all samples from EBOV survivors were simultaneously reactive with NP and GP (90/94) or with NP, GP, and VP40 (87/94). Considering as positive for past EBOV infection only samples that reacted with EBOV NP and GP, sensitivity was 95.7% and specificity increased to 99.1%. Comparing results with commercial EBOV NP and GP enzyme-linked immunosorbent assays (ELISAs; Alpha Diagnostic, San Antonio, TX), lower sensitivity (92.5%) and high specificity (100%) were observed with the same positivity criteria. Samples from EBOV survivors cross-reacted with GP from Sudan Ebola virus (GP-SUDV) (81.9%), GP from Bundibugyo Ebola virus (GP-BDBV) (51.1%), GP from Reston Ebola virus (GP-RESTV) (9.6%), VP40-SUDV (76.6%), and VP40-BDBV (38.3%). Overall, we developed a sensitive and specific high-throughput serological assay, and defined an algorithm, for epidemiological surveys with humans.KEYWORDS Ebola virus, serology, Luminex, recombinant proteins S ince 1976 and the first formal identification of Ebola virus (EBV) disease in Yambuku, in the Democratic Republic of Congo (DRC), a total of 25 outbreaks have been reported today among humans in Africa, with a fatality rate between 25% and 90% (1). Twenty-three of the 25 Ebola virus disease outbreaks occurred in Central Africa, while two occurred in West Africa, including the most devastating outbreak in Guinea/ Liberia/Sierra Leone between 2013 and 2016, infecting more than 28,000 persons and causing 11,308 deaths (2, 3). For unknown reasons, no Ebola virus disease epidemics were detected between the 1979 outbreak in DRC and the 1994 outbreak in Côte D'Ivoire. However, since 1999, the frequency of outbreaks has increased (1, 2, 4). There are currently five species of Ebola viruses: Zaire Ebola virus (EBOV) documented in the

show abstract

mentioning

confidence: 59%

Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus

et al. 2017

View full text Add to dashboard Cite

show abstract

De tol van dodelijke infectieziekten wereldwijd

Ende

Huits

2015

Bijblijven

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Filovirus epidemic in 1956 in Bili, DRC

Cited by 2 publications

References 0 publications

Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus

Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus

De tol van dodelijke infectieziekten wereldwijd

Contact Info

Product

Resources

About